PRKN and intrahepatic cholangiocarcinoma: Cannabinoid receptor-interacting protein 1 (CNRIP1) inhibits intrahepatic cholangiocarcinoma cell proliferation, invasion, and migration by modulating the CNRIP1/Parkin/PKM2 pathway, thereby enhancing Parkin-PKM2 interactions and facilitating PKM2 ubiquitination and degradation (110).